Transgene TNG.PA · EUR

Its shares trade on Euronext Paris under the ticker TNG.PA. It has been listed since 25 March 1998. In the fiscal year to 31 December 2024, it reported revenue of €6.1m and a net loss of €34.0m. At that date it held total assets of €42.2m and shareholders' equity of €15.2m.

Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Alessandro RivaChairman of the Board, Chief Executive Officer, Member of the Management Committee, since 2022€740,000
• Mr. Christophe AncelChief Quality Officer and Qualified Pharmacist, Director of Pharmaceutical Operations and Chief Pharmacist - Deputy Chief Executive Officer, Member of the Management Committee€184,000
• Ms. Lucie LarguierChief Financial Officer, Member of the Management Committee
• Ms. Christelle SchwoererChief Human Resources Officer, Member of the Management Committee
• Ms. Simone SteinerChief Technology Officer, Member of the Management Committee
• Dr. Maurizio CeppiChief Scientific Officer, Member of the Management Committee
• Mr. John FelittiGeneral Counsel, Corporate Secretary, Member of the Management Committee
• Dr. Emmanuelle DochyChief Medical Officer, Member of the Management Committee
• Mr. James WentworthChief Business Officer, Member of the Management Committee
• Mr. Jean-Luc BelingardNon-Executive Director
• Mr. Michel de PuchesseNon-Executive Director
• Ms. Sandrine FloryNon-Executive Director - Representative of TSGH

Overall

57

Environment

35

Social

99

Governance

37

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.